RVTY · Revvity, Inc.

Current Thesis

The leg being bought is the wet-lab layer underneath AI drug discovery. On the 2026-08-04 Q2 call, management said instrumentation backlog was the strongest in three to four years and credited demand from AI-driven drug discovery customers — the argument being that generated hypotheses still have to be tested with reagents, instruments and biological data. That claim landed on top of a Diagnostics segment growing 11% organically and a signed exit from the structurally impaired China immunodiagnostics business. The narrative is accelerating: the re-rate is only weeks old, RBC opened new coverage on 2026-09-01 and KeyBanc raised its target to $165 on 2026-09-04, and the shares closed 2026-09-04 at $130.22, 0.5% under the $130.94 52-week high after a three-month price change of +29.9%.

The qualifier sits in the same evidence: RBC's initiation carries a $135 target against that $130.22 close, which is the first dated marker of an analyst arriving at the story and finding it already priced.

Bullish and bearish views on Revvity, Inc.

The model's bull view on Revvity, Inc. (RVTY), in brief: Q2 2026 print, 2026-08-04: revenue $711M, pro forma organic growth +3%, adjusted EPS $1.41 versus the $1.21 consensus cited in post-print coverage, adjusted operating margin 29.3%. The bear view: Half the company shrank in Q2: Life Sciences revenue $359M, organic -3%, with the software line down approximately double digits per coverage of the Q2 slide deck. Both cases follow in full.

Bull Case

• Q2 2026 print, 2026-08-04: revenue $711M, pro forma organic growth +3%, adjusted EPS $1.41 versus the $1.21 consensus cited in post-print coverage, adjusted operating margin 29.3%.
• Guidance raised the same day: FY26 organic growth to 4–5% from 3–4%, adjusted EPS to $5.30–$5.40 (up $0.10), revenue $2.83–$2.86B, adjusted operating margin ~28.7%.
• Diagnostics is carrying the model: $352M revenue, +11% organic in Q2, with Reproductive Health up mid-teens organically and immunodiagnostics ex-China accelerating to high single digits.
• Backlog claim, Q2 call 2026-08-04: strongest instrumentation backlog in three to four years. This is the load-bearing number for the whole AI-adjacent framing, and it is management-sourced rather than independently observable.
• Portfolio surgery: definitive agreement to divest the China immunodiagnostics business, roughly 6% of FY2025 revenue, cited by management as a persistent policy-headwind and low-return line. Closing expected by end of 2027.
• Leverage came down: a EUR 500M bond was repaid in July 2026, taking net debt/EBITDA to 2.5x.
• Sell-side momentum: KeyBanc maintained Overweight and raised its target to $165 on 2026-09-04.

Bear Case

• Half the company shrank in Q2: Life Sciences revenue $359M, organic -3%, with the software line down approximately double digits per coverage of the Q2 slide deck. The AI-validation story is being told over a segment that is currently contracting.
• The guide requires acceleration: organic growth printed +3% in Q2 against a full-year 4–5% frame, so the second half has to do the work.
• Valuation carries the beat: forward P/E of 23.05 (stockanalysis.com, 2026-09-05) on a mid-single-digit organic grower whose margin guide is ~28.7%.
• The marginal analyst is neutral: RBC initiated Sector Perform on 2026-09-01 with a $135 target — barely above the last close, not a re-rate call.
• The divestiture is slow: China immunodiagnostics stays consolidated until a close expected by end of 2027, leaving policy and execution exposure inside the reported numbers for five-plus quarters.
• No company-dated event inside 30 days changes a number. Three conference appearances between 2026-09-09 and 2026-09-15 are fireside chats, not order-book disclosures; the next print that can confirm or break the backlog claim is the Q3 report expected in late October.

Setup & Price Structure

• Last completed daily close 2026-09-04 at $130.22, against a 52-week high of $130.94 — 0.5% below it. RSI(14) reads 73.4.
• The 50-day moving average sits at $116.40 and the 200-day at $102.36 (stockanalysis.com, 2026-09-05). Both slope up; price sits well clear of each, which is what a +29.9% three-month move produces and also what leaves no shelf directly under the tape.
• No consolidation has formed since the 2026-08-04 gap. The first structural level beneath the market is the 50-day at $116.40; below that, the post-print advance is gone entirely.
• Crowding observables, stated as observables: RSI(14) 73.4 with the close 0.5% off the 52-week high; short interest 6.42M shares, 6.26% of float, on 111.59M shares outstanding (stockanalysis.com, 2026-09-05); fresh sell-side attention inside seven days (new coverage 09-01, target raise 09-04); target dispersion of $135 to $165 straddling a $130.22 close. The filing feed reviewed for this note shows no recent insider transactions — that is an absence in one feed, not proof that none occurred.
• What the structure does not offer is a defined-risk entry shelf: the nearest one sits back at the 50-day, so anything bought at the highs is underwritten by the Q3 print rather than by the chart.

Catalyst Calendar (next 30 days)

• 2026-09-09 — Wells Fargo 21st Annual Healthcare Conference, 8:45 a.m. ET, CEO Prahlad Singh. First public management commentary since the 08-04 print; the backlog claim either gets repeated with detail or it does not.
• 2026-09-14 — Morgan Stanley 24th Annual Global Healthcare Conference, 8:30 a.m. ET, CFO Max Krakowiak. Margin path to ~28.7% and the China divestiture timeline are the CFO-level questions.
• 2026-09-15 — Baird 2026 Global Healthcare Conference, 9:05 a.m. ET, SVP Steve Willoughby.
• ~2026-10-27 (est.) — Q3 2026 results. Outside the 30-day window and the only event that can put a number against the instrument-backlog narrative. Date unconfirmed; the Q2 report came 2026-08-04 before market open.

What Would Change Our Mind

The fundamental break comes first. The backlog claim is management-sourced and unverifiable until it converts: a Q3 print (expected late October) that leaves Life Sciences organic growth negative, trims FY26 organic growth back toward 3–4%, or discloses no follow-through on instrument orders would remove the reason the multiple expanded in August. A second, quieter break: the three September conference appearances passing without incremental order-book or backlog detail while the shares remain pinned against $130.94 — that is the shape of the story going saturated as coverage arrives without a widening bid.

On the tape, a weekly close below $116 loses the 50-day average at $116.40 and gives back the entire post-08-04 advance; that condition ends the re-rate leg regardless of what the guidance says.

The opposite datapoint also exists: sustained weekly closes above $135 — RBC's initiation target — with Q3 confirming instrument conversion would say the neutral incremental analyst was early rather than right.

Correlation Notes

• No theme cluster in the current registry carries this name, so this is a single-name read and nothing here leans on a group move.
• The natural comparable set is Thermo Fisher, Danaher, Agilent and Bruker; shared drivers are pharma and biotech R&D budgets, NIH and academic funding, instrument tariffs and China demand policy. A funding or capex headline that hits the group hits this name whatever the backlog says.
• Five-year beta is 1.09 (stockanalysis.com, 2026-09-05) — this does not trade as a defensive.
• Internally the two halves decouple: Reproductive Health and newborn screening track birth rates and screening-panel adoption, not the instrument cycle, which is why Diagnostics printed +11% organic in Q2 while Life Sciences printed -3%.
• Once the China immunodiagnostics divestiture closes (expected end of 2027, per the 2026-08-04 disclosure), roughly 6% of FY2025 revenue and its associated China policy sensitivity leave the reported base — a structural change in the name's correlation profile, not a near-term one.